DTO/SB/08B (00.08)

Approved for use through 03/31/2007. OMB 0661-0031

Under the Paperwork Reduction Act of 1995, no persons at Substitute for form 1449/PTO	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
1	Application Number	10/574,054		
INFORMATION DISCLOSURE	Filing Date	March 29, 2006 Shue, Youe-Kong		
STATEMENT BY APPLICANT	First Named Inventor			
(Use as many sheets as necessary)	Art Unit	TBA 1623		
(Examiner Name	TEA Ganapathy Krishnan		
Sheet 1 of 3	Attorney Docket Number	8031-013-US		

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	_
Initials*	No. the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/G.K./		AYRAL, et. al. Rheumatology, Vol 35, 14-17	
		AYRAL, et. al. Annals of the Rheumatic Diseases 2002 vol. 61 suppl. 1	
		HUGHES, et. al. Rheumatology (Oxford) 2002; 41:279-84	
		HEDBOM, et. al. Cell Mol Life Sci 2002; 59:45-53	
		AMIEL et. al. J Orthop Res 1986; 4:162-172	
		ALTMAN et. al. Am J Med. 1983 Oct 31;75(4B):50-5	
		ADEBOWALE et. al. Biopharm Drug Dispos 2002; 23:217-25	
		AGHAZADEH-HABASHI et. al. J Pharm Pharm Sci 2002; 5(2):181-4	
		CHANG et. al. Osteoarthritis Cartilage 1997; Sep;5:357-72	
/G.K./		DE MATTEI et. al. Osteoarthritis Cartilage 2002; 10:816-25	

/Ganapathy Krishnan/ 09/14/2008 Signature Considered *EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through distribution if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Examiner

containeds. Includes cays or use form with next communications or apparent.

A policidant's unity as children designation improving organization places at clerk mark here if English linguage Translation is attached.

A policidant's unity as children designation improving organization in the contains a bornative by the public which is to lise (and, by the USPTO to process) an expolication. Confidentially is governed by 38 U.S.C. 122 and 37 CPR 1.4.

To process an expolication. Confidentially is governed by 38 U.S.C. 122 and 37 CPR 1.4.

The surface of the policy of the complete despitation from the to USPTO. Then will very depending upon the including analysis of the complete despitation from the full service. The will very depending upon the including analysis of the complete the first marker suggestions for reducing this burden, should be sent to the Chief Information Office, Or. 8 or 1450, Ascendaria, VA 2231-4456. D. ON OTS SEND FEES OR CONNETTEED FORMS TO THIS ADDRESS. SENDER. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (09-06)

Approved for use through 03/31/2007, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	re required to respond to a collection of information unless it contains a valid QMB control number. Complete if Known			
	Application Number	10/574,054		
INFORMATION DISCLOSURE	- 1	March 29, 2006		
STATEMENT BY APPLICANT	First Named Inventor	Shue, Youe-Kong		
(Use as many sheets as necessary)	Art Unit	TBA 1623		
,,	Examiner Name	TBA Ganapathy Krishnan		
Sheet 2 of 3	Attorney Docket Number	8031-013-US		

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS	
nitials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/G.K./		ELSAID et. al. Osteoarthritis Cartilage. 2003;11:673-80	
		FINGL et al., in The Pharmacological Basis of Therapeutics, 1975, Ch. 1 p. 1	
		GELETKA et. al. Best Pract Res Clin Rheumatol. 2003 Oct;17:791-809	
		KERIN et. al. Cell Mol Life Sci 2002;59:27-35	
		REGINSTER et. al. Lancet 2001; 357:251-6	
		REISSIG et. al. J. Biol. Chem. 1955 217: 959-966	
		MCALINDON, Best Pract Res Clin Rheumatol 1999; 13(2):329-44	
		SANDY et. al. Arch Biochem Biophys 1999; 367:258-64	T
		SHIKHMAN et. al. J Immunol 2001; 166:5155-60	
/G.K./		SETTON et. al. Osteoarthritis Cartilage 1999; 7:2-14	T

Examiner	/Ganapathy Krishnan/	Date	09/14/2008
Signature		Considered	00/1 // 2000

Signature Considered whether or not datation is in conformance with HEPE 605. Draw line through clastion if not in conformance and not considered, include copy of this form with next communication to applicant.

1-Applicant's unique clastical designation number (optional). Applicant is not by passes a check mark here if English language Translation is attached. This collection of information is required to obtain or retain a benefit by the public which is to the (end by the USPTO This collection of information is required to obtain or retain a benefit by the public which is to the (end by the USPTO traces) are application. Confiderable by governed by 30.5C. 1/2 and 37 CPR 1.14. This collection is estimated to be see hours to complete, including self-ening, imperiors, and submitting the comprehigh spiculation form to the USPTO. Time will vary depending upon the individual cases. Any comments on the Tademark Ciflos. (P.O. Box 145). Measurable values have been some facility this budget, subdut be sent to the Chef information Officer, US. Petert and Tademark Ciflos. (P.O. Box 145). Alexandria, VA 22313-1456.

PTO/SB/08B (09-06)

Approved for use through 03/31/2007, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Denember Deduction Act of 100E, no names ----

Substitute for form 1449/PTO	Complete if Known			
	Application Number	10/574,054		
INFORMATION DISCLOSURE	Filing Date	March 29, 2006		
STATEMENT BY APPLICANT	First Named Inventor	Shue, Youe-Kong		
(Use as many sheets as necessary)	Art Unit	∓BA 1623		
(coo as many shoets as necessary)	Examiner Name	THA Ganapathy Krishnan		
Sheet 3 of 3	Attorney Docket Number	8031-013-US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/G.K./		SMITH et. al. J Rheumatol 1997; 24:365-71	
		SETNIKER et. al. Arzneimittelforschung 2001; 51:699-725	
		SILVER et. al. Crit Rev Biomed Eng 2001; 29:373-91	
		SAH et. al. J Orthop Res 1997 Mar;15:197-203	
/G.K./		YOSHIOKA et. al. Osteoarthritis Cartilage 1996; 4:87-98	
		-	

Examiner	/Ganapathy Krishnan/	Date	09/14/2008
Signature	/Ganapany Mondan/	Considered	00/1 //2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include Cody of the form win next communication to appeared.

Applicant's unique citation designation manuface (optional). Applicant's is to place a check mark here if English language Translation is attached.

Applicant's unique citation designation manuface (optional). Applicant is not place as check mark here if English language Translation is attached.

In application, confidentially is governed by 30 U.S.C. 122 and 37 CR1 1.14. The confident is better the place of the confidential place in the complete application from the to USFTO. The wall very depending upon the individual case. An increased on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Crief Information Officer, U.S. Palent and Trademist Citics, Pol. 20x 1450, Alexandris, VA 2231-4456, D.O NOT SERVIPE CES OR COMPLETED FORMS TO THIS ADDRESS. SERVIPE. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.